Determinants of Increased Fibrinogen in COVID-19 Patients With and Without Diabetes and Impaired Fasting Glucose

Zhenzhou Wang, MD¹, Zhe Du, MD¹, Xiujuan Zhao, MD¹, Fuzheng Guo, MD¹, Tianbing Wang, MD¹, and Fengxue Zhu, MD¹

Abstract

Background: To investigate the factors associated with elevated fibrinogen (Fbg) levels in COVID-19 patients with and without diabetes (DM) and impaired fasting glucose (IFG).

Methods: According to whether or not their glucose metabolism was impaired, COVID-19 patients were subdivided into 2 groups: 1) with DM and IFG, 2) control group. Their demographic data, medical history, signs and symptoms, laboratory results, and final clinical results were analyzed retrospectively.

Results: 28 patients (16.3%) died during hospitalization, including 21 (29.2%) in group 1 and 7 (7.0%) in group 2 (P < 0.001). Fbg levels in groups 1 and 2 were higher than the normal range, at 5.6 g/L (IQR 4.5–7.2 g/L) and 5.0 g/L (IQR 4.0–6.1 g/L), respectively (P = 0.009). Serum ferritin levels, C-reactive protein (CRP), interleukin-6 (IL-6), IL-8, tumor necrosis factor-α (TNF-α), triglycerides (TG) were significantly increased in group 1 compared to those in the control. TG levels were 1.3 mmol/L in patients with DM and IFG, while that in group 1 was 1.8 mmol/L. Multiple linear regression showed that the predicting factors of Fbg in the control group were serum ferritin and CRP, R² = 0.295; in group 1, serum ferritin, CRP, and TG, R² = 0.473.

Conclusions: Fbg in all COVID-19 patients is related to serum ferritin and CRP involved in inflammation. Furthermore, in COVID-19 patients with insulin resistance, Fbg is linearly positively correlated with TG. This suggests that regulation of TG, insulin resistance, and inflammation may reduce hypercoagulability in COVID-19 patients, especially those with insulin resistance.

Keywords

COVID-19, diabetes, impaired fasting glucose, fibrinogen, triglyceride

Date received: 21 November 2020; revised: 10 January 2021; accepted: 1 February 2021.

Introduction

Patients with severe coronavirus disease (COVID-19) without other thrombotic risk factors still exhibit various thrombotic events, including microvascular thrombosis, venous thrombosis and pulmonary thromboembolism, and acute arterial thrombosis. ¹ COVID-19-associated coagulopathy (CAC) is an acute thrombosis and is an important cause of organ failure and death in patients. ¹,² The pathogenesis of CAC is still unclear, and many factors, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, inflammation, vascular endothelial injury, coagulation, and fibrinolysis imbalance may be involved. ²,³ Among these, an increased fibrinogen (Fbg) level has been proven as an important part of CAC. ¹,³,⁴ Currently, anticoagulant and fibrinolytic drugs are used in the treatment of CAC. ⁵,⁶

People with diabetes mellitus (DM) are more likely to experience complications and death due to COVID-19. ⁷,⁸ Laboratory tests show that COVID-19 patients with elevated glycosylated hemoglobin (HbA1c) have higher cytokines and Fbg. ⁹ The aims of this study is to answer these questions: What factors are related to the increase of Fbg in COVID-19 patients? Is there a difference between patients with and without DM? To investigate these questions, we conducted a small...
retrospective study to provide preliminary insight into the pathogenesis and treatment of CAC.

Materials and Methods

Study Participants and Their Evaluation

Overall, 176 patients were diagnosed with COVID-19 in the Wuhan Tongji Hospital wards between February 9 and 28, 2020. Four patients were excluded (2 patients treated with glucocorticoids and immunosuppressants for renal transplantation and chronic systemic lupus erythematosus, one hemolytic anemia patient, and one patient with myelosuppression after leukemia chemotherapy); thus, 172 were included in the study. The enrolled patients were divided into 2 groups: (1) 72 patients in the DM and impaired fasting glucose (IFG) group, (2) 100 patients in the control group. Patients in the control group had normal fasting glycemia without DM history. In the group with DM and IFG, 32 patients (44.4%) had type 2 DM history, 19 (26.4%) were newly diagnosed with DM, and 21 (29.2%) had high fasting glycemia. Patients with DM history received one or more oral hypoglycemic drugs (metformin was most used, followed by acarbose) before admission, and 12 (16.7%) received insulin therapy before admission. DM and IFG diagnosis were based on 2019 WHO diagnostic criteria for DM.10 HbA1c was not used as a diagnostic criterion because of acute viral infections in the patients. COVID-19 was diagnosed according to the Diagnosis and Treatment Plan for Chinese New Coronavirus Pneumonia (7th Edition) 11 issued by the National Health Commission of the People’s Republic of China. The basic demographic characteristics of the patients are provided in Table 1.

This was a retrospective cohort study. Therefore, data on the patient’s characteristics, medical history, symptoms and signs, laboratory test results, and final clinical outcomes were retrieved from the electronic medical record system. Laboratory test results reported white blood cell and lymphocyte count values as minimum values during the entire hospitalization. Conversely, serum ferritin, interleukin (IL), tumor necrosis factor-α (TNF-α), c-reactive protein (CRP), triglyceride (TG), lactate dehydrogenase (LDH), and Fbg levels were reported as maximum values. All laboratory parameters were measured after 8 hours of fasting. All patients were treated according to the “Chinese New Coronavirus Pneumonia Diagnosis and Treatment Plan (7th Edition)”11 and were followed up until April 6, 2020. The study was approved by the Ethics Committee of Peking University People’s Hospital.

Statistical Analyses

Categorical variables were presented as frequencies and percentages, and continuous variables were presented as median and interquartile range (IQR). One-way analysis of variance (ANOVA) was used to calculate the difference between groups for continuous variables that fit the normal distribution, and non-parametric tests were used for non-normally distributed continuous variables. The chi-square test was used to categorical variables. Multiple linear regression was used to analyze the related factors of Fbg. P < 0.05 was considered

Table 1. Demographics and Baseline Characteristics of COVID-19 Patients.

| Variable                        | No. (%) | Control  | DM and IFG | P-value |
|--------------------------------|---------|----------|------------|---------|
| Age in years, median (IQR)     | 66.0 (55.3–72.0) | 64.0 (48.5–69.0) | 68.0 (60.3–76.3) | 0.000   |
| Sex                            |         |          |            |         |
| Male                           | 86 (50.0) | 42 (42.0) | 44 (61.1)  | 0.013   |
| Female                         | 86 (50.0) | 58 (58.0) | 28 (38.9)  |         |
| Comorbidities                  |         |          |            |         |
| Hypertension                   | 80 (46.5) | 41 (41.0) | 39 (54.2)  | 0.088   |
| Cardiovascular disease         | 30 (17.4) | 16 (16.0) | 14 (19.4)  | 0.684   |
| Pulmonary disease              | 14 (8.1)  | 6 (6.0)   | 8 (11.1)   | 0.265   |
| Cerebrovascular disease        | 9 (5.2)   | 5 (5.0)   | 4 (5.6)    | 1.000   |
| Chronic kidney disease         | 13 (7.6)  | 8 (8.0)   | 5 (6.9)    | 1.000   |
| Maintenance hemodialysis       | 11 (6.4)  | 7 (7.0)   | 4 (5.6)    | 0.763   |
| Thyroid disease                | 3 (1.7)   | 2 (2.0)   | 1 (1.4)    | 1.000   |
| Signs and symptoms             |         |          |            |         |
| Fever                          | 114 (66.3) | 62 (62.0) | 52 (70.7)  | 0.192   |
| Cough                          | 113 (65.7) | 71 (71.0) | 42 (58.3)  | 0.104   |
| Fatigue                        | 73 (42.4)  | 44 (44.0) | 29 (40.3)  | 0.643   |
| Shortness of breath            | 109 (63.4) | 62 (62.0) | 47 (65.3)  | 0.749   |
| Myalgia                        | 30 (17.4)  | 16 (16.0) | 14 (19.4)  | 0.684   |
| Diarrhea                       | 21 (12.2)  | 13 (13.0) | 8 (11.1)   | 0.815   |
| Mortality                      | 28 (16.3)  | 7 (7.0)   | 21 (29.2)  | 0.000   |
| %SaO2 on admission, median (IQR) | 95.0 (90.0–97.0) | 95.5 (92.0–97.0) | 93.0 (85.3–96.8) | <0.001 |

IQR, interquartile range; DM, diabetes mellitus; IFG, impaired fasting glucose.
therapy at the bedside. SaO₂ without oxygen inhalation on
infection, they underwent intermittent renal replacement
hemodialysis due to chronic kidney disease. After SARS-CoV-
also increased significantly compared to that in the control
2.4 mmol/L), which not only exceeded the normal range but
level in the DM and IFG group was 1.8 mmol/L (IQR 1.3–
were 1.6 mmol/L (IQR 1.1–2.2 mmol/L) in all patients and
¼
5.0 g/L (IQR 4.0–6.1 g/L), respectively (P
higher than the normal range, at 5.6 g/L (IQR 4.5–7.2 g/L) and
were previously treated with mechanical ventilation (Table 1).

The correlation analysis between the 2 groups of measure-
ment data and Fbg showed that the related factors of Fbg in the
control group were serum ferritin, CRP, IL-6, IL-8, and TNF-α, while in the group with DM and IFG were lymphocytes, serum ferritin, CRP, and TG. The correlation analysis between the 2 groups of measurement data and Fbg showed that the related factors of Fbg in the control group were serum ferritin, CRP, IL-6, IL-8, and TNF-α, while in the group with DM and IFG were lymphocytes, serum ferritin, CRP, and TG (Table 3). To solve the problem of multicollinearity among related factors, we included them in multiple linear regression equations. The results showed that the factors influencing Fbg in the control group were serum ferritin and CRP, R² = 0.295, while in the DM and IFG group, serum ferritin, CRP, and TG, R² = 0.473 (Table 4).

Discussion
Fbg, as an acute phase reactive protein, is involved in coagula-
tion and inflammation. On the other hand, inflammation can lead to a significant increase in the expression of Fbg in the

| Variable                     | Normal range | Total (n = 172) | Median (IQR) Control (n = 100) | DM and IFG (n = 72) | P-value |
|------------------------------|--------------|-----------------|--------------------------------|---------------------|---------|
| Fasting blood glucose (mmol/L) | 4.1–6.05     | 5.7 (5.1–7.1)   | 5.2 (4.9–5.6)                  | 7.9 (6.5–11.6)      | 0.000   |
| Fbg (g/L)                    | 2.0–4.0      | 5.2 (4.1–6.6)   | 5.0 (4.0–6.1)                  | 5.6 (4.5–7.2)       | 0.009   |
| Leukocytes (×10⁹/L)          | 3.5–9.5      | 5.0 (4.1–6.2)   | 4.8 (4.0–5.7)                  | 5.3 (4.1–6.9)       | 0.031   |
| Lymphocytes (×10⁹/L)         | 1.1–3.2      | 0.8 (0.5–1.4)   | 0.9 (0.7–1.5)                  | 0.7 (0.4–1.1)       | 0.006   |
| Serum ferritin (μg/L)        | 30.0–400.0   | 664.6 (349.4–1519.9) | 527.0 (310.2–1153.9)          | 990.7 (433.7–2299.5) | 0.000   |
| LDH (U/L)                    | 135.0–225.0  | 286.0 (234.0–431.3) | 286.0 (225.5–369.3)          | 292.0 (242.3–514.8) | 0.067   |
| CRP (mg/L)                   | <1.0         | 36.1 (53.105.2) | 27.0 (4.1–66.0)               | 59.0 (11.1–185.4)   | 0.000   |
| IL-1β (pg/mL)                | <5.0         | 5.0 (5.0–5.0)   | 5.0 (5.0–5.0)                  | 5.0 (5.0–5.0)       | 0.327   |
| IL-2 (U/mL)                  | 223.0–710.0  | 714.0 (440.0–1193.0) | 655.0 (403.0–1023.0)        | 802.0 (509.0–1477.0) | 0.054   |
| IL-6 (pg/mL)                 | <7.0         | 15.3 (40.0–57.4) | 10.2 (3.0–40.3)               | 36.7 (8.7–116.9)    | 0.014   |
| IL-8 (pg/mL)                 | <6.20        | 13.1 (6.8–30.9) | 10.8 (6.4–22.5)               | 25.6 (7.4–43.4)     | 0.018   |
| IL-10 (pg/mL)                | <9.1         | 5.0 (5.0–7.6)   | 5.0 (5.0–6.4)                  | 5.0 (5.0–12.6)      | 0.209   |
| TNF-α (pg/mL)                | <8.1         | 9.2 (6.1–13.7)  | 8.3 (5.7–13.3)                | 10.6 (7.3–15.8)     | 0.011   |
| TG (mmol/L)                  | <1.7         | 1.6 (1.1–2.2)   | 1.3 (0.9–2.0)                  | 1.8 (1.3–2.4)       | 0.046   |

CRP, C-reactive protein; DM, diabetes mellitus; IFG, impaired fasting glucose; IQR, interquartile range; IL, interleukin; TG, triglycerides; LDH, lactate dehydrogenase; TNF-α, tumor necrosis factor-α; Fbg, fibrinogen.
Improperly elevated Fbg can lead to hypercoagulability and excessive inflammation. Fbg can act as a ligand for the surface receptors (such as VE-cadherin, ICAM-1, αvβ3, αvβ1, αvβ5, and α2β2) of leucocytes, vascular endothelial cells, platelets, fibroblasts, and smooth muscle cells. Among them, G protein-coupled protease activated receptors can control the expression of cytokines and chemokines. Our research shows that inflammation-related cytokines and Fbg are elevated in COVID-19 patients, especially in patients with DM and IFG. Multiple regression analysis showed that serum ferritin and CRP related to inflammation affect Fbg levels, and are positively correlated with Fbg. This indicates that in COVID-19 patients, there may also be a mutual driving effect between inflammation and Fbg.

Our research shows that in COVID-19 patients with DM and IFG, Fbg is not only related to serum ferritin and CRP involved in inflammation but also positively related to TG. Insulin resistance is one of the important pathophysiological mechanisms of IFG and Type 2 DM, and hypertriglyceridemia is one of the typical features of insulin resistance. Studies on visceral obesity and insulin resistance have shown that TG is degraded by lipoprotein lipase to produce free fatty acids (FFA), which leads to a significant increase of FFA in plasma. FFA can activate the NF-κB pathway and increase the liver expression of various pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and monocyte chemoattractant protein 1 (MCP-1). In addition, elevated plasma FFA can also promote Fbg production and reduce fibrinolytic capacity. Studies have shown that Fbg levels are related to insulin resistance. The use of rosiglitazone in patients with type 2 DM to improve insulin resistance can significantly reduce the level of Fbg. In patients with metabolic syndrome, the application of the lipid-lowering drug fenofibrate not only improves blood lipids but also improves insulin resistance and reduces Fbg.

Recently, research by Ehrlich et al suggests that elevated lipid metabolism may underlie aspects of COVID-19 pathogenesis, and fenofibrate can treat COVID-19 by disrupting lipid metabolism. We compared the parameters in non-survivors to those in survivors, with significant increases in Fbg, TG, and cytokines in non-survivors (Supplemental Table 1). An increased level of Fbg is one of the characteristics of CVC. Friedrich et al showed that even with conventional antithrombotic therapy, Fbg levels peaked at the third week of the disease and remained significantly elevated at the eighth week. The persistently high Fbg level may affect the occurrence of thromboembolic events, especially in diabetic patients with higher Fbg levels. Ranucci et al described the correlation between IL-6 and Fbg levels. Similarly, our study also showed that Fbg in all COVID-19 patients is related to serum ferritin and CRP involved in inflammation. Moreover, to the best of our knowledge, our study is the first to associate hyperfibrinogenemia with elevated TG levels in insulin-resistant COVID-19 patients. Our preliminary research suggests it may be possible to reduce the level of TG to reduce Fbg in such patients while undergoing conventional thrombotic treatment, thereby reducing the risk of thrombosis.

Of course, as a retrospective study with a small sample size, our research has limitations. In particular, we lack indicators to quantitatively assess insulin resistance. Using the triglyceride and glucose (TyG) index as indicators of insulin resistance, the study by Ren et al showed that the TyG index was significantly associated with an increased risk of severe case and mortality of COVID-19, after controlling for potential confounders (OR for severe case, 2.9, P = 0.007; OR for mortality, 2.9, P = 0.016). Unfortunately, their study did not provide data on Fbg and other coagulation related factors. Therefore, we still need to do more research.

Conclusions
Fbg in all COVID-19 patients is related to serum ferritin and CRP involved in inflammation. Furthermore, in COVID-19 patients with insulin resistance, Fbg is linearly positively correlated with TG. This suggests that regulation of TG, insulin resistance, and inflammation may reduce hypercoagulability in COVID-19 patients, especially those with insulin resistance.

Acknowledgments
The authors would like to acknowledge the contribution of the survey team members.

Author contributions
Zhenzhou Wang, Zhe Du. These authors contributed equally. ZD and ZZW designed the study, wrote and revised the manuscript. TBW and FXZ analyzed the data. XJZ and FZG reviewed the manuscript. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate
The study was approved from by the Ethics Committee of Peking University People’s Hospital, and written informed consent was obtained from all participants before enrolment in the study. All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the Declaration of Helsinki.

Table 4. Multiple Regression Analysis of Fbg in COVID-19 Patients With and Without DM and IFG.

| Variable     | Control group |             | DM and IFG group |             |
|--------------|---------------|-------------|------------------|-------------|
|              | Standardized coefficient | P-value | Standardized coefficient | P-value |
| Serum ferritin | 0.206         | 0.049      | 0.348            | 0.006      |
| CRP          | 0.4           | 0.000      | 0.246            | 0.014      |
| TG           | 0.748         | 0.000      |                  |            |

CRP, C-reactive protein; DM, diabetes mellitus; IFG, impaired fasting glucose; TG, triglycerides.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Natural Science Foundation of Beijing municipality (7204321) and Peking University People’s Hospital Scientific Research Development Funds (RDY-2019-02).

ORCID ID
Fengxue Zhu https://orcid.org/0000-0002-6018-1822

Supplemental Material
Supplemental material for this article is available online.

References
1. Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19: manifestations and management. Cleve Clin J Med. 2020;87(8):461-468.
2. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54-67.
3. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040.
4. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575-e582.
5. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865.
6. Correa TD, Cordioli RL, Campos Guerra JC, et al. Coagulation pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747-1751.
7. Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12(5):1179-1186.
8. Yan Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe COVID-19 with diabetes. BMJ Open Diabetes Res Care. 2020;8(1):e001343.
9. Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract. 2020;164:108214.
10. The Chinese novel coronavirus pneumonia diagnosis and treatment plan (trial version seven). Updated November 11, 2020. Accessed November 11, 2020. http://www.nhc.gov.cn/zyygj/s7653p/202003/46c9294a7dfe4ceff80dc7f5912eb1989.shtml
11. Hoppe B. Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and inflammation. Thromb Haemost. 2014;112(4):649-658.
12. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34(1):43-62.
13. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318(5):E736-E741.
14. Mcrae K, McCrae K. Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and inflammation. Thromb Haemost. 2014;112(4):649-658.